SGLT2I The paradigm change in diabetes managementPraveen Nagula
Just like ARNI, SGLT2I have changed the face of diabetes management and they have a good profile in multimodality management because of pleiotropic effects
MANAGEMENT OF DIABETES IN CHRONIC KIDNEY DISEASE (Special reference to Use of...Dr. Om J Lakhani
Talk on MANAGEMENT OF DIABETES IN CHRONIC KIDNEY DISEASE (Special reference to Use of Metformin In CKD).
Presented on 25th June 2017 at THE METFORMIN MEET in Vadodara, India
SGLT2I The paradigm change in diabetes managementPraveen Nagula
Just like ARNI, SGLT2I have changed the face of diabetes management and they have a good profile in multimodality management because of pleiotropic effects
MANAGEMENT OF DIABETES IN CHRONIC KIDNEY DISEASE (Special reference to Use of...Dr. Om J Lakhani
Talk on MANAGEMENT OF DIABETES IN CHRONIC KIDNEY DISEASE (Special reference to Use of Metformin In CKD).
Presented on 25th June 2017 at THE METFORMIN MEET in Vadodara, India
Insulin Initiation : When We should Start with Basal Insulin?mataharitimoer MT
Insulin Initiation : When We should Start with Basal Insulin?
Dr. Agus Taolin , SpPD, FINASIM | PAPDI CABANG BOGOR
Disampaikan pada acara PIT VI IDI Kota Bogor | 9 Nopember 2013
Inpatient Diabetes Management - How to Control Hyperglycemia inhsopitalUsama Ragab
Inpatient Diabetes Management
By Dr. Usama Ragab Youssif
Lecturer of Medicine Zagazig University
Why we need this lecture?
Diabetes inhospital is common problem
Increased diabetes morbidities
Increased mortality
Strict Glycemic Control in Critically ill patients: The Demise of another ver...Prof. Mridul Panditrao
Prof. Mridul M. Panditrao tries to explain the pros and cons about the good strategy, whcih became controversial and almost obsolete. He also tries to tract the whole aspect of the phenomenon and reviews/ RCTs/
Strict (Tight) Glycemic control (SGC/TGC), as it is called, was and still is a good strategy. It can be defined as maintenance of the blood glucose level in the range of 80-110 mg /dl. with help of dose variable and intensive insulin therapy (IIT). Since its introduction, there have been conflicting reports of its efficacy and complications. This resulted in slow but steady neglect of this very good idea leading to its almost complete demise.
An effort has been made in this review, to impartially analyze all the available evidence and try to find the reasons for the negative publicity which led to the neglect or worse still, the wrong use of this protocol. Some suggestions for fair and proper implementation of the strategy are put forward.
etc/
Insulin Initiation : When We should Start with Basal Insulin?mataharitimoer MT
Insulin Initiation : When We should Start with Basal Insulin?
Dr. Agus Taolin , SpPD, FINASIM | PAPDI CABANG BOGOR
Disampaikan pada acara PIT VI IDI Kota Bogor | 9 Nopember 2013
Inpatient Diabetes Management - How to Control Hyperglycemia inhsopitalUsama Ragab
Inpatient Diabetes Management
By Dr. Usama Ragab Youssif
Lecturer of Medicine Zagazig University
Why we need this lecture?
Diabetes inhospital is common problem
Increased diabetes morbidities
Increased mortality
Strict Glycemic Control in Critically ill patients: The Demise of another ver...Prof. Mridul Panditrao
Prof. Mridul M. Panditrao tries to explain the pros and cons about the good strategy, whcih became controversial and almost obsolete. He also tries to tract the whole aspect of the phenomenon and reviews/ RCTs/
Strict (Tight) Glycemic control (SGC/TGC), as it is called, was and still is a good strategy. It can be defined as maintenance of the blood glucose level in the range of 80-110 mg /dl. with help of dose variable and intensive insulin therapy (IIT). Since its introduction, there have been conflicting reports of its efficacy and complications. This resulted in slow but steady neglect of this very good idea leading to its almost complete demise.
An effort has been made in this review, to impartially analyze all the available evidence and try to find the reasons for the negative publicity which led to the neglect or worse still, the wrong use of this protocol. Some suggestions for fair and proper implementation of the strategy are put forward.
etc/
Care of Diabetic Patients in a Hospital Setting Symposia, presented in Milot, Haiti at Hôpital Sacré Coeur.
CRUDEM’s Education Committee (a subcommittee of the Board of Directors) sponsors one-week medical symposia on specific medical topics, i.e. diabetes, infectious disease. The classes are held at Hôpital Sacré Coeur and doctors and nurses come from all over Haiti to attend.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
Inpatient hyperglycemia.ver3 (3)
1. Management of inpatient
hyperglycaemia in non–critically
ill patients with type 2 diabetes
Under guidance of - Dr. RAJEEV PATNI
Fellow Institute of Endocrinology, Univ of Sydney,
NSW, Australia
Consultant Endocrinologist & Diabetologist
Santokba Durlabhji Memorial Hospital Jaipur
1
Presented by- Dr. MOHAMMAD REHAN
DNB Resident
2. Overview
• Introduction
• Definition and diagnosis of inpatient hyperglycaemia
• Classification of hyperglycaemia
• Pathogenesis of hyperglycaemia in hospitalized patients
• Glycaemic targets
• Treatment of hyperglycaemia
• Sliding scale vs Basal-bolus
• Insulin regimens
• Insulin therapy in specific clinical situations
• Summary
• Case discussion
2
3. Introduction
• Diabetes is a major healthcare challenge of the century and is epidemic
worldwide.
• Global prevalence of Diabetes patients- 415 million (41.5 Cr)
• Prevalence in India- 69.2 million (6.92 Cr); expected to cross 100 million mark
by year 2040.
• Hyperglycaemia is common in hospitalized patients
• 12-25% of hospitalized patients have pre-existing diabetes
• 50% of patients admitted to ICU have prediabetes or diabetes
• Of the hospitalized patients, almost a third have significant hyperglycaemia
IDF Diabetes Atlas,7th Edition, 2015. International Diabetes Federation http://www.diabetesatlas.org/
Umpierrez GE, et al. JCEM: January 2012, 97 (1):16–38.
Umpierrez GE. J Clin Endocrinol Metab.2002;87:978–982.
3
4. Introduction
• Hyperglycaemia is a risk factor for adverse outcomes during acute illness,
surgery or steroid treatment
• Insulin is the mainstay of treatment of hyperglycaemia in hospitalized
patients
• Hyperglycaemia in inpatients is a strong predictor of in-hospital mortality
• Hyperglycaemia has been shown to increase the risk of mortality in
hospitalized patients irrespective of diabetic status
4
IDF Diabetes Atlas,7th Edition, 2015. International Diabetes Federation http://www.diabetesatlas.org/
Umpierrez GE, et al. JCEM: January 2012, 97 (1):16–38.
Umpierrez GE. J Clin Endocrinol Metab.2002;87:978–982.
5. Definition and diagnosis of inpatient hyperglycaemia
• In-hospital hyperglycaemia is defined as glucose value greater than 7.8
mmol/litre (140 mg/dl)
• Hyperglycaemia occurs not only in patients with known diabetes but also
in those with previously undiagnosed diabetes and others with “stress
hyperglycaemia”
• Stress hyperglycaemia may be defined as hyperglycaemia which may
occur during an acute illness or stress, and that resolves once the illness
improves or stress is over.
Umpierrez GE, et al. JCEM: January 2012, 97 (1):16–38.
RSSDI Recommendations for “In Hospital Management of Hyperglycemia in Indian Patients”. 2016, under publication. 5
6. Classification of hyperglycemia
• Hyperglycaemia in hospitalised patients can be further classified into 3
broad categories1:
RSSDI Recommendations for “In Hospital Management of Hyperglycemia in Indian Patients”. 2016, under publication. 6
Previously diagnosed Existing hyperglycaemia prior to hospitalization
Previously
undiagnosed
At admission:
Fasting Blood Sugar (F) > 126 mg/dl,
Random Blood Sugar Level (R) > 200 mg/dl,
HbA1c > 6.5%
Stress
hyperglycaemia
At admission:
HbA1c < 5.7%
During hospitalization: F > 126 mg/dl, R > 200 mg/dl
Post discharge: Normoglycaemia
7. Pathogenesis of hyperglycaemia in hospitalized patients
Mehta KC. Chapter 62. Medicine Update. 2005;300–303. Available at
http://www.apiindia.org/medicine_update_2005/chapter_62.pdf
7
Stress hormones
cortisol, epinephrine Glucose Production
Lipolysis
FFAs
FFAs
+
Glucose Uptake
Glucose
Fatty Acids
Illness
8. Adverse effects of hyperglycaemia
8
Illness
Glucose
Fatty Acids
Hemodynamic insult
Electrolyte losses
Oxidative stress
Myocardial injury
Hypercoagulability
Altered immunity
Wound healing
Inflammation
Endothelial function
Mehta KC. Chapter 62. Medicine Update. 2005;300–303. Available at
http://www.apiindia.org/medicine_update_2005/chapter_62.pdf
9. Glycaemic targets for non-critically ill patients
• Premeal blood glucose (BG) <140 mg/dl
• Postmeal/random BG <180 mg/dl
• BG target <200 mg/dl is reasonable for
• Patients with low life expectancy, terminal illness or increased risk of
hypoglycaemia
• Reassess if BG <100 mg/dl
• Modify if BG <70 mg/dl
Umpierrez GE, et al. JCEM: January 2012, 97 (1):16–38.
Moghissi ES. Diabetes Care 2009 Jun; 32(6): 1119-1131
9
10. Treating hyperglycaemia in non-critically ill patients
• Insulin is the preferred treatment for hyperglycaemia in non-critically ill
hospitalized patients with diabetes
• For patients with T1DM- basal-bolus
• For T2DM patients who are already on oral agents and have well
controlled glycaemia continue existing therapy
RSSDI Recommendations for “In Hospital Management of Hyperglycemia in Indian Patients”. 2016, under publication. 10
11. • Indications of using insulin in T2DM
1) Lean individuals or those with severe weight loss
2) Individuals with underlying renal or hepatic disease that precludes oral
drugs
3) Hospitalised or acutely ill individuals
4) Glycemic target not achieved after combination oral therapy
11
12. Treating hyperglycaemia in non-critically ill patients
• Non-insulin agents
• Generally not preferred because of
• recurrent vomiting, sepsis, enteral/parenteral feeding, pancreatic disorders, renal failure
• Common problems with oral antidiabetic drugs (OADs)
• Sulphonylureas (SUs): prolonged and severe hypoglycaemia if meal is skipped or
oral intake is poor
• Metformin: ↑risk of lactic acidosis
• Thiazolidinediones (TZD): take several weeks for the full effect
• DPP-4 Inhibitors: generally contraindicated in patients with pancreatic disease
• GLP-1 Agonists: cause nausea; best avoided in hospitalised patients
• SGLT2 inhibitors: can predispose to genito-urinary infections
RSSDI Recommendations for “In Hospital Management of Hyperglycemia in Indian Patients”. 2016, under publication.
Moghissi ES. Diabetes Care 2009 Jun; 32(6): 1119-1131
12
13. Insulin regimens for treating non-critically ill in-hospital patients
• Insulin is the preferred choice
• Sliding Scale Insulin (SSI) was a common approach in hospital settings
• Problems with SSI
Umpierrez GE. Diabetes Care. 2007;30:2181–2186.
Umpierrez GE. DiabetesCare. 2011;34:256–261.
13
• It is based on the assumption that
insulin resistance is uniform in all
patients
• One dosing formula for all
• Chases glucose values; dosing decided
based on hyperglycaemia after it has
happened
• Under-estimates the total daily insulin
requirement
• Does not differentiate basal and
prandial requirements
• Ineffective glycaemic
control
• ↑Hypoglycaemia risk
• Increased hospital stay
14. Sliding-Scale regular Insulin (SSI) vs Basal-Bolus (RABBIT-2 Trial)
Umpierrez GE. Diabetes Care 30:2181–2186, 2007 14
Changes in blood glucose concentrations in patients treated
with glargine plus Glulisine (•) and with SSI (○). *P < 0.01; ¶P <
0.05.
Mean blood glucose concentration in subjects who remained with
severe hyperglycemia despite increasing doses of RI per the sliding-
scale protocol (○). Glycemic control rapidly improved after switching
to the basal-bolus insulin regimen (•). P < 0.05.
Treatment with basal insulin & bolus insulin resulted in significant improvement in glycaemic control as compared to sliding-scale
regular insulin (SSI) alone. Use of basal-bolus insulin regimen was safe & associated with a low rate of hypoglycaemic events
15. Sliding-Scale regular Insulin (SSI) vs Basal-Bolus (RABBIT-2 Surgery Trial)
Umpierrez GE. DiabetesCare. 2011;34:256–261. 15
Changes in blood glucose concentration after the
1st day of treatment with basal-bolus with glargine
once daily plus glulisine before meals (○) and with
SSI 4-times daily (●). *P < 0.001, ŧP = 0.02, †P =
0.01.
Glucose levels before meals and bedtime. Premeal and
bedtime glucose levels were higher throughout the day in the
SSI group (●) compared with basal-bolus regimen (○).
Basal-bolus treatment with glargine once daily plus glulisine before meals improved glycemic control and reduced
hospital complications compared with SSI in general surgery patients
16. Insulin regimens
Insulin regimen for these patients should include three components:
• ‘Basal-bolus’ is the preferred insulin regimen
• Patients who are well controlled on premix insulins can continue premix
RSSDI Recommendations for “In Hospital Management of Hyperglycemia in Indian Patients”. 2016, under publication. 16
Basal insulin • Insulin glargine once daily
• Insulin detemir once or twice daily
• NPH twice daily
Nutritional insulin • Rapid acting analogues or regular insulin
(RI) given subcutaneously before meals
Correctional insulin • Rapid acting analogues or RI given
subcutaneously before meals
17. Estimating subcutaneous (SC) insulin dose
• Patients on insulin and well controlled at home can be maintained with same regimen with
adjustments
- based on meals, activity, effects of illness and the effects of other medications
RSSDI Recommendations for “In Hospital Management of Hyperglycemia in Indian Patients”. 2016, under publication.
17
TDD calculation TDD: 80% of calculated
TDD
For insulin naïve: Total dose as per body
weight
Use 80% of calculated
TDD for starting s/c
insulin
Give:
Basal insulin: 50% of TDD
Bolus insulin: 50% of TDD
Ideal body weight 0.4-0.5 u/kg
Obese 0.5-0.6 u/kg
Lean or renal compromised 0.3-0.4 u/kg
From IV to S/C transition
Calculate the insulin requirement in previous 6 hours of
stable control of BG and multiply by 4 for total amount of
insulin needed in 24 hours or the actual total insulin
requirement in the last 24 hours.
18. 18
Calculation of the dose with correctional factor
Basal dose Correctional bolus (CB)
Glargine Single dose AM/PM Blood glucose (BG) – 100 =
CB
Correction Factor (CF)
CF= 1500/TDD (Regular
insulin)
Or
CF=1800/TDD (Analogue
insulin)
Detemir Given 12 hourly split dose
NPH Given 12 hourly split dose
Degludec Single dose
For basal dose correction:
PM basal: Check FBG for 2 days, ↑2u of basal till FBG 80-120mg%
AM basal: Check pre-dinner for 2 days, ↑2u of basal till BG 90-110mg%
Bolus dose
Total bolus dose ÷ 3 With breakfast, lunch, dinner
For bolus: regular, Aspart, Glulisine, Lispro can be used
1. RSSDI Recommendations for “In Hospital Management of Hyperglycemia in Indian Patients”. 2016, under publication.
19. 19
Example of calculation
TDD: 30U
-Basal: 15U AM/PM
-Bolus 15U (Regular)
Bolus 5U-5U-5U before each 3 meals
+ Additional correctional bolus for BG not
at target at any meal
Additional Correctional Bolus:
Estimated BG: 250
CF: 1500/30=50
CB = 250 -100 = 150 = 3U
CF 50 50
Total meal dose: 5U+3U = 8 units
1. RSSDI Recommendations for “In Hospital Management of Hyperglycemia in Indian Patients”. 2016, under publication.
Insulin in renal compromised patients
• Renal compromised patients need a
lower dose of insulin
• Depending on GFR, target goals
may be relaxed
• Targets for renal patients
HbA1c FBGL(mg/dl) 2h PPBSL
(mg/dl)
Normal GFR,
microalbuminuria +
6.5-7 80-120 < 180
Predialysis (Cr.Cl < 10) < 7.5 100-140 < 180
Dialysis 7.5 – 8 100-140 < 200
Post renal transplant 6.5-7 80-120 < 180
20. Insulin therapy in specific clinical situations
• Peri-operative management
• Stable glycaemic control prior to the elective procedure with HbA1c target of <
8%
• If HbA1c is >9% or BG >200 mg/dl and surgery cannot be postponed → first
achieve blood glucose control prior to procedure
• During surgical procedure, maintain BG levels 140-180mg/dl
• Minor surgical procedures
• Managed without changing the pre-operative anti-hyperglycaemic treatment
regimen
• If patient has uncontrolled hyperglycaemia it needs to be controlled and then
surgery can be planned.
RSSDI Recommendations for “In Hospital Management of Hyperglycemia in Indian Patients”. 2016, under publication. 20
21. Insulin therapy in specific clinical situations
• For morning procedures:
• The day prior to procedure→ take full dose of medications- insulin and OADs at
dinner
• Patient remains nil by mouth until the procedure is complete in the morning
• Usual dose of insulin and/or OADs with breakfast by mid-morning.
• If procedure is delayed & BG are above target (>180 mg/dl) →start insulin
infusion
• Subcutaneous (S.C.) correction short acting insulin dose if facility for infusion is
not available
RSSDI Recommendations for “In Hospital Management of Hyperglycemia in Indian Patients”. 2016, under publication. 21
22. Insulin therapy in specific clinical situations
• For patients who are not on insulin (on OADs or GLP-1 analogues)
• All OADs and GLP-1 analogues
• continued on the day prior to procedure
• omitted on the morning of procedure
• resumed once the patients resume their diet
• Metformin
• Need not be discontinued unless there is renal, cardiac and hepatic
impairment
• For procedures requiring radio-contrast administration
• discontinue metformin 24 hours prior to the procedure.
• restart after confirming normal renal function after 48 hours.
RSSDI Recommendations for “In Hospital Management of Hyperglycemia in Indian Patients”. 2016, under publication. 22
23. Management of hyperglycaemia during obstetrics
procedures, C-Section and vaginal delivery
• Day care obstetric procedures (cervical cerclage, amniocentesis) do not require more
than 6-8 hours of overnight fasting
• Maintain BG between 70-140 mg/dl during and immediately after the procedure.
Intrapartum glucose management
• Uncontrolled maternal hyperglycaemia during the labour → foetal hyperinsulinism
and neonatal hypoglycaemia
• Maternal BG target during delivery - 70 to 140 mg/dl
• Separate insulin and glucose infusions
• Start insulin infusion at 0.5 -1 U/hr
• 5% Dextrose or dextrose normal saline [DNS] - 80-125 ml/h.
RSSDI Recommendations for “In Hospital Management of Hyperglycemia in Indian Patients”. 2016, under publication. 23
24. Glycaemic management during caesarean section
and induction of labour
• A planned caesarean section should be posted early in the morning
• Usual dose of OADs and night-time insulin the day prior to surgery
• Withhold OADs and insulins on surgery day
• If procedure is delayed and light breakfast is allowed by obstetrician, give half the
dose of intermediate insulin S.C.
• Maintain BG levels between 70-140 mg/dl by glucose infusion
24RSSDI Recommendations for “In Hospital Management of Hyperglycemia in Indian Patients”. 2016, under publication.
25. Patients receiving enteral nutrition
• Hyperglycaemia is a common complication of enteral feedings
• Enteral formulas with low carbohydrate & modified fat content should be used if
possible
• Treat persistent hyperglycemia with insulin
• Insulin regimens
• once-daily glargine insulin
• premixed human 70/30 insulin every 8 hours
• combination of NPH every 12 hours and RI every 6 hours
• Starting TDD of insulin 0.3-0.6 U/kg
• adjusted daily based on glucose response and the amount of correctional insulin that was
required the previous day
• Add 80% of correctional insulin to the long- or intermediate-acting insulin next day
RSSDI Recommendations for “In Hospital Management of Hyperglycemia in Indian Patients”. 2016, under publication. 25
26. Sample insulin requirement calculation for a patient on enteral feeding
Sample: Insulin dose calculation for 80kg patient with a BMI of 24kg/m2 on continuous
enteral feeding
Step 1. TDD calculation
TDD=0.4x80 (0.4units/kg body weight x body weight) = 32 units
Step 2. Insulin dose based on type of insulin
Insulin glargine/degludec 32 units subcutaneously daily
Insulin NPH 16 units subcutaneously twice daily
Step 3. Correctional scale estimation
Low correctional scale insulin is most appropriate for patients requiring an
estimated TDD of 32 units. Order correction dose every 4 hours with rapid
acting analogues and every 6 hours with RI.
26RSSDI Recommendations for “In Hospital Management of Hyperglycemia in Indian Patients”. 2016, under publication.
27. Patients receiving total parenteral nutrition (TPN)
• Hyperglycaemia occurs commonly with total parenteral nutrition (TPN)
• For mild hyperglycaemia add RI to TPN 0.1 units for every gram of carbohydrate
• If glucose remains, adjust insulin dose in TPN daily by adding 80% of the previous
day’s correctional insulin
• If BG are very high use IV insulin
• Once stable IV rate is determined extrapolate it to 24 hr TDD with 75% of this
added to TPN.
RSSDI Recommendations for “In Hospital Management of Hyperglycemia in Indian Patients”. 2016, under publication. 27
28. CASE STUDY 2
• A 50-year-old man with diabetes (BMI = 30.2 kg/m2) is admitted for
pneumonia treatment with a RBG level of 300 mg/dL and an HbA1c level
of 10.8 %; OADs are discontinued, and blood glucose testing is ordered
before meals and at bedtime.
31
How will you initiate insulin therapy in
this non-critical care setting
29. Initiating Insulin Therapy
• Calculated total daily dose (TDD) of insulin:
• 0.6 U/kg × 90kg = 54 U
• Basal dose = 50% of TDD at bedtime
– 50% of 54 U = 27 U basal insulin at bedtime
• Total bolus dose = 50% of TDD evenly distributed 1/3 at each meal
– 27 U÷3 meals = 9 U rapid-/short-acting insulin before each meal (t.i.d.)
• Give additional rapid-/short-acting insulin as per standard supplemental
(correction) insulin schedule
32
30. Components to be integrated in the discharge plan
• Medications at discharge are based on HbA1c
• Previously diagnosed,
• HbA1c < 8% - continue pre-hospitalisation treatment
• HbA1c > 8% - treatment needs to be intensified
• Addition of another oral antidiabetic medication
• Intensification of the doses of pre-existing medications (or insulin)
• Initiation of basal insulin for patients not on insulin
• HbA1c is not available
• with fair glycaemic control - pre-admission anti-diabetic medication continued
• with poor glycaemic control - pre-admission medications to be titrated
RSSDI Recommendations for “In Hospital Management of Hyperglycemia in Indian Patients”. 2016, under publication.
Bogun M. Clinical Therapeutics/Vol 35, Number 5, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23688537
42
31. Components to be integrated in the discharge plan
• Previously undiagnosed,
• HbA1c 6.5% -7% - life style modification, follow up and monotherapy with an oral glucose
lowering agent may be considered
• HbA1c > 7 % - OHA and / or insulin if indicated
• Stress hyperglycaemia,
• HbA1c < 5.7% - follow up recommended
• HbA1c 5.7%–6.4% - treated as per recommendations for prediabetes
• Follow up: within 15 days of discharge with the specialist and / or
primary care physician.
RSSDI Recommendations for “In Hospital Management of Hyperglycemia in Indian Patients”. 2016, under publication.
Bogun M. Clinical Therapeutics/Vol 35, Number 5, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23688537
43
32. Case study
44
Mr RKS, a 45-year-old male patient, is a known case of type 2 diabetes for five years.
There is no history of hypertension, coronary artery disease, or any other complications of diabetes. He
has been on treatment with glimepiride 4 mg daily, metformin (extended release) 2 grams daily, and
atorvastatin 10mgs daily.
He developed acute pain abdomen and recurrent vomiting for 24 hours for which he was hospitalised.
He was diagnosed with acute renal colic. His blood glucose at the time of admission was 275 mg/dl
and his HbA1C was 8.3%. He is haemodynamically stable. His renal functions were normal. He was
initiated on conservative treatment with anti-emetics and painkillers.
You have been asked to take care of his hyperglycaemia.
34. 46
Type 2
diabetes
patient
• Hospitalised in non-critical care setting
• With uncontrolled glycaemia prior to
admission
• On oral agents prior to admission
• Able to accept orally
35. • Guidelines for management of hyperglycaemia in such a patient involves:
• Initiating regular glucose monitoring.
• Stop oral agents.
• Calculating total daily requirement of insulin.
• Giving 40% of the dose as insulin glargine subcutaneously or 20% of the dose as
NPH subcutaneously, given twice daily.
• Dividing 40% of the calculated dose equally in three doses of rapid acting insulin,
given before meals.
• Adding correction bolus based on pre-meal BG values.
• BG monitoring before meals, at bedtime, in fasting state, whenever
hypoglycaemia is suspected.
47
36. • Targeting fasting BG at 110-140 and other glucose values at 140-180mg/dl.
• Modifying basal insulin dose based on fasting BG/ fasting and before dinner BG.
• Modifying bolus dose of insulin by adding correctional doses used on previous
day to the calculated bolus doses.
• Once improved and accepting normal meals, basal insulin may be continued,
bolus insulin can be stopped and oral agents added, and patient can be
discharged on basal plus oral therapy for hyperglycaemia with advice:
• to monitor BG regularly
• how to interpret BG values
• to watch for hypoglycaemia
• to make adjustments based on BG monitoring
• to come for follow up after 1-2 weeks.
48
37. Insulin
The Most Powerful Agent We Have to Control
Glucose
• Oldest of the currently available medications
• Most clinical experience available
• Most effective agent for lowering glycemia
• No maximum dose beyond which therapeutic effect will not occur
• Beneficial effects on triglyceride and HDL cholesterol levels
Nathan DM, Buse JB, Davidson MB, et al. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus
Algorithm for the Initiation and Adjustment of Therapy. Diabetes Care, Volume 32, Number 1, January 2009
38. Polonsky, N Engl J Med 1996; 334: 777-783
Normal Insulin Secretion
39. Main Types of Insulin Analogs
• Rapid Acting Analogs- For providing
prandial/mealtime/bolus doses
• Basal Insulin Analogs- For providing basal levels of
insulin during interprandial and nocturnal periods
• Premix Insulin Analogs- providing both prandial and
basal insulin in single injection
40. Comparison of Human Insulins/Analogs
Insulin Onset of Duration of
Preparations Action Peak Action
Regular 30-60 min 2-4 h 6-10 h
NPH/lente 1-2 h 4-8 h 10-20 h
Ultralente 2-4 h Unpredictable 16-20 h
Lispro/Aspart 5-15 min 1-2 h 4-6 h
Glargine 1-2 h Flat ~24 h
Detemir 1 – 2 h 3 – 9 h 17 – 23 h
43. Need for Rapid-acting Insulin Analogs
• Mimic physiologic insulin profile (1st and 2nd Phase)
• Administration at mealtime (no waiting)
• Improved postprandial glycemic control
• Lower risk of late hypoglycemia
44. Limitations of NPH, Lente,
and Ultralente
• Do not mimic basal insulin profile
• Variable absorption
• Pronounced peaks
• Less than 24-hour duration of action
• Cause unpredictable hypoglycemia
• Major factor limiting insulin adjustments
45. 4:00 16:00 20:00 24:00 4:00
Breakfast Lunch Dinner
8:0012:008:00
Time
Basal Insulin
lispro lispro lispro
Plasmainsulin
Long-acting Insulin Analogs with Rapid Acting Analogs
Provide Ideal Basal Bolus Insulin Profile
46. Premix Analogs
• Have been shown to be effective for
achieving glycemic control and they may
also decrease the risk for hypoglycemia
• Specially beneficial in patients with
inconsistent mealtimes and lifestyles and in
those whose adherence to treatment may
be enhanced by a simple treatment
regimen
47. Insulin Analogs
• Provide more closer physiological insulin delivery
• Greater convenience due to flexible timing of injections
• Provide almost identical or better long term glycemic control
• Associated with somewhat lower episodes of hypoglycemia
• May be more weight friendly
• Long-term studies awaited on cancer risk
• Complete data still lacking on use during pregnancy
• No information on benefits in late complications
48. Key Advantages of Basal Insulin Analogs
• Once daily injection in significant number of subjects
• Appears to be more effective than NPH in real life over several years
• Has less weight gain than premix in BOT
• Have better efficacy/hypoglycaemia ratio than NPH
• Reduces the risk of hypoglycaemia compared to NPH when initiating
insulin in all patient types, including the elderly
• Associated with less risk of nocturnal hypoglycaemia than NPH
• Has a significantly better QoL compared with NPH
49. Summary: Benefits of Using Premix Insulin Analogs
• Convenient- Easy initiation and same insulin can be intensified
• Effective-
• Better A1c control than long-acting analogs and other agents as shown in several meta-analysis
• Twice-daily regimens provides almost similar glycemic control as an intense regimen of multiple
daily injections (MDI)
• No mixing errors- By combining the insulins themselves, patients can encounter problems
with mixing technique and inaccurate dosing ratios, potentially reducing the effectiveness of
the short-acting insulin.
• Less detailing required- Basal bolus regimen requires patients to remember multiple types of
pens and doses
• Mealtime flexibility with Premix Analogs- Premixed insulin analogs provide quick absorption
and rapid PPG-lowering effects provide potential for improved glycemic control